Literature DB >> 10593486

An anti-HIV strategy combining chemotherapy and therapeutic vaccination.

B Rosenwirth1, W M Bogers, I G Nieuwenhuis, P T Haaft, H Niphuis, E M Kuhn, N Bischofberger, V Erfle, G Sutter, P Berglund, P Liljestrom, K Uberla, J L Heeney.   

Abstract

Combination chemotherapy using potent anti-retroviral agents has led to significant advances in the clinical management of human immunodeficiency virus (HIV) disease. However, the emergence of multiple drug-resistant mutants, the high need for compliance to adhere to demanding drug-dosing schemes, and the remaining toxic side-effects of drugs make the perspective of life-long treatment unattractive and possibly unrealistic. Therefore, means must be sought to shorten the time span during which treatment is necessary. Such means could be to stimulate an efficient immune response during the period of low virus load and restored CD4 + cell levels, which might be capable of keeping the virus under long-lasting control after treatment is stopped. Here we tested this concept of combined chemotherapy/ therapeutic vaccination in a non-human primate model. Rhesus macaques chronically infected with the chimeric simian/human immunodeficiency virus (SHIV) containing the HIV type 1 (HIV-1) HXBc2 gene for reverse transcriptase (RT) in the genomic background of simian immunodeficiency virus (SIV)(mac239) (RT-SHIV) were treated with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), a potent anti-HIV drug. When virus load had decreased significantly, we immunized with SIV genes env, gag/pol, rev, tat, and nef inserted in two different expression vector systems. Four weeks after the second immunization, drug treatment was stopped. Animals were monitored to determine if virus load stayed low or if it increased again to the original levels and if CD4+ T-cell levels remained stable. Humoral and cellular immune responses were also measured. This combined chemotherapy/ therapeutic vaccination regimen induced a significant reduction in the steady-state level of viremia in one out of two chronically infected rhesus macaques. Chemotherapeutic treatment alone did not achieve reduction of viremia in two chronically infected animals. The nature of the immune responses assumed to have been induced by vaccination in one out of the two monkeys remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593486     DOI: 10.1111/j.1600-0684.1999.tb00270.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  4 in total

1.  Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.

Authors:  Elias G Argyris; Geethanjali Dornadula; Giuseppe Nunnari; Edward Acheampong; Chune Zhang; Ketti Mehlman; Roger J Pomerantz; Hui Zhang
Journal:  Virology       Date:  2006-07-21       Impact factor: 3.616

2.  In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.

Authors:  Zandrea Ambrose; Valerie Boltz; Sarah Palmer; John M Coffin; Stephen H Hughes; Vineet N Kewalramani
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.

Authors:  Koen K A Van Rompay; Kristin A Trott; Kartika Jayashankar; Yongzhi Geng; Celia C LaBranche; Jeffrey A Johnson; Gary Landucci; Jonathan Lipscomb; Ross P Tarara; Don R Canfield; Walid Heneine; Donald N Forthal; David Montefiori; Kristina Abel
Journal:  Retrovirology       Date:  2012-07-17       Impact factor: 4.602

4.  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Authors:  Koen K A Van Rompay; Jeffrey A Johnson; Emily J Blackwood; Raman P Singh; Jonathan Lipscomb; Timothy B Matthews; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger; Walid Heneine; Thomas W North
Journal:  Retrovirology       Date:  2007-04-06       Impact factor: 4.602

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.